Medical devices, healthcare technology and the business of care
510(k) clearance · K262168

QIAstat-Dx BCID GN Plus AMR Panel

QIAGEN GmbH · Decision date Sep 24, 2026

MEDTECHLEDGER EXPLANATIONK262168

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-09-24 for QIAstat-Dx BCID GN Plus AMR Panel, submitted by QIAGEN GmbH of Hilden, Germany, under 510(k) number K262168. The application was received 06/26/2026 and reviewed as a traditional 510(k) by the Microbiology panel; the classification product code is PEN, under regulation number 866.3365, for Gram-Negative Bacteria And Associated Resistance Markers.

SESE in this database denotes 510(k) clearance, not premarket approval. The public record does not describe the specific components, assay targets, or changes relative to any predicate device, and no decision summary content is available in the public information. The page lists no third-party review, no combination product status, and no authorized predetermined change control plan; clinical performance data and labeling are not included here and would need to be read from the FDA decision documents.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Sep 24, 2026
FDA decision documents: 510(k) Premarket Notification - FDA

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262168
Regulatory pathway
510(k) premarket notification
Applicant
QIAGEN GmbH
Product code
PEN
Decision code
SESE
Decision date
Sep 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Gram-Negative Bacteria And Associated Resistance Markers.

Applicant
QIAGEN GmbH
Product code
PEN
FDA device class
2

FDA decision timeline

  1. K262168 received

    Application receipt date recorded by FDA.

  2. K262168 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

QIAGEN GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Hilden

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records